caa a22 4500 475847555 CHVBK 20180406123918.0 cr unu---uuuuu 170329e20000501xx s 000 0 eng 10.1023/A:1008960710415 doi (NATIONALLICENCE)springer-10.1023/A:1008960710415 Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C [Elektronische Daten] [L. Kleinman, M.W. Zodet, Z. Hakim, J. Aledort, C. Barker, K. Chan, L. Krupp, D. Revicki] Evidence exists demonstrating that infection with hepatitis C virus impairs health-related quality of life, but less is known about the effect of fatigue, a common symptom, on everyday life. The psychometric properties of the fatigue severity scale (FSS) were explored to determine suitability as an outcome measure in clinical trials. The FSS includes nine items developed to measure disabling fatigue and a visual analog scale (VAS) to measure overall fatigue. Using baseline data from three clinical trials (n = 1225) involving chronic hepatitis C patients, scaling and psychometric characteristics of the FSS were assessed. The SF-36 was also used in the trials. Item response theory analysis demonstrated that the FSS items can be placed along a single homogenous domain, fatigue. Internal consistency reliability was 0.94. Test-retest reliability was 0.82 for the total score and 0.80 for the VAS. The total score and the VAS were significantly correlated with the SF-36 vitality subscale (r = −0.76 and r = −0.76 respectively). Correlations with other SF-36 subscales were moderate (r = −0.46 to r = −0.67, all p < 0.0001). In summary, the FSS possesses good psychometric properties. Kluwer Academic Publishers, 2000 Chronic hepatitis C nationallicence Clinical trials nationallicence Fatigue severity scale nationallicence Item response theory nationallicence Reliability nationallicence Validity nationallicence Kleinman L. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut Zodet M.W. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut Hakim Z. Hoffman-La Roche, Inc., Palo Alto, CA, USA aut Aledort J. Hoffman-La Roche, Inc., Nutley, NJ, USA aut Barker C. Hoffman-La Roche, Inc., Palo Alto, CA, USA aut Chan K. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut Krupp L. Department of Neurology, State University of New York at Stonybrook, Stonybrook, NY, USA aut Revicki D. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut Quality of Life Research Kluwer Academic Publishers 9/5(2000-05-01), 499-508 0962-9343 9:5<499 2000 9 11136 https://doi.org/10.1023/A:1008960710415 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1008960710415 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kleinman L. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut NATIONALLICENCE 700 1- Zodet M.W. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut NATIONALLICENCE 700 1- Hakim Z. Hoffman-La Roche, Inc., Palo Alto, CA, USA aut NATIONALLICENCE 700 1- Aledort J. Hoffman-La Roche, Inc., Nutley, NJ, USA aut NATIONALLICENCE 700 1- Barker C. Hoffman-La Roche, Inc., Palo Alto, CA, USA aut NATIONALLICENCE 700 1- Chan K. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut NATIONALLICENCE 700 1- Krupp L. Department of Neurology, State University of New York at Stonybrook, Stonybrook, NY, USA aut NATIONALLICENCE 700 1- Revicki D. Center for Health Outcomes Research, MEDTAP® International, Inc., Bethesda, MD, USA aut NATIONALLICENCE 773 0- Quality of Life Research Kluwer Academic Publishers 9/5(2000-05-01), 499-508 0962-9343 9:5<499 2000 9 11136 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer